Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Type2diabetes, Type 2 Diabetes Treated W...
Phase NA
Enrollment 700
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The CARING study assesses the health benefits of nutrition education for Blue Cross Blue Shield subscribers, as well as potential healthcare cost savings to subscribers and the insurance company.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Low-fat, vegan diet — The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.

Primary Outcomes

  • Medical Utilization (16 weeks, 1 year, and 2 years)
  • Body Weight (16 weeks, 1 year, and 2 years)
  • Plasma Lipid Concentrations (16 weeks, Every 6 months during the 2-year follow-up period)
  • HbA1C (16 weeks, Every 6 months during the 2-year follow-up period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-07-11
Completion: 2028-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Physicians Committee for Responsible Medicine
Collaborators: Blue Cross Blue Shield, Mayo Clinic
Principal Investigators:
  • Neal Barnard, MD (PRINCIPAL_INVESTIGATOR) - Physicians Committee for Responsible Medicine
Contact Information
Study Contact:
Macy Sutton, MS
202-527-7363
msutton@pcrm.org
Arathi Jayaraman
ajayaraman@pcrm.org
Physicians CFR Medicine
2025277363
ajayaraman@pcrm.org
Physicians Committee for Responsible Medicine
Interventions
  • Behavioral: Low-fat, vegan diet — The intervention diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Participants will also be guided to favor foods with a low glycemic index. Animal products and added oils will be excluded. The diet is designed to derive approximately 10% of energy from fat, approximately 10-15% of energy from protein, and the remainder from mostly complex carbohydrates. The diet will also provide approximately 40 g of fiber per day.
Study Locations (1 sites)
Physicians Committee for Responsible Medicine, Washington D.C., District of Columbia 20016 United States
Eligibility Criteria
Inclusion Criteria: 1. Blue Cross Blue Shield subscriber continuously enrolled for the prior 12 months 2. Male or female 3. Age at least 18 years 4. Have a diagnosis of type 2 diabetes 5. Ability and willingness to participate in all components of the study, including: 1. Following a plant-based diet for the initial 16 weeks of the study; 2. Attending weekly online classes for the initial 16 weeks of the study; and 3. Keeping physical activity level consistent throughout the initial 16 weeks of the study. Exclusion Criteria: 1. Diabetes mellitus type 1 or history of any endocrine condition that would affect body weight, such as a pituitary abnormality or Cushing's syndrome 2. Smoking during the past six months 3. Alcohol consumption of more than 2 drinks per day or the equivalent, episodic increased drinking (e.g., more than 2 drinks per day on weekends), or a history of alcohol abuse or dependency followed by any current use 4. Current or unresolved past drug abuse 5. Recently gave birth, pregnant, or plans to become pregnant before or during the study period 6. Unstable medical or psychiatric status 7. Cancer diagnosis 8. Chronic kidney disease, stage 4 or 5 9. Evidence of an eating disorder 10. Lack of English fluency 11. Bariatric surgery in the last 6 months 12. Dementia 13. Institutional custodial care 14. End of life 15. Palliative Care 16. Actively engaged in specific BCBSM diabetes programs and case management programs
Conditions Depression
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, multi-center, open-label study in which patients with depression who responded to an open-label treatment with intermittent theta burst stimulation (iTBS) will receive this procedure as maintenance therapy. The patients will be randomized to two study arms. The arms differ in the frequency of stimulation (standard iTBS (5 treatments every working day for one week) vs. accelerated iTBS (5 treatments in one day)). For purposes of effect size estimation an interim analysis will be done after half of the patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: intermittend theta burst stimulation — intermittend theta burst stimulation

Primary Outcomes

  • relapse (number of patients who have a relapse for depression) (33 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-04-25
Completion: 2026-02-28
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Berthold Langguth, MD, Ph.D.
Principal Investigators:
  • Berthold Langguth, Prof. (PRINCIPAL_INVESTIGATOR) - University Hospital of Regensburg, Department of Psychiatry and Psychotherapy at the Bezirksklinikum
Contact Information
Study Contact:
Martin Schecklmann, Prof.
+49-941-941-2054
martin.schecklmann@medbo.de
Mohamed Abdelnaim, Dr.
+49-941-941-1256
mohamed.abdelnaim@medbo.de
Berthold Langguth
+49-941-941-2099
berthold.langguth@medbo.de
Department of Psychiatry and Psychotherapy, University of Regensburg
Interventions
  • Device: intermittend theta burst stimulation — intermittend theta burst stimulation
Study Locations (1 sites)
Department of Psychiatry and Psychotherapy, University of Regensburg, Regensburg, 93055 Germany
Eligibility Criteria
Inclusion Criteria: * adult women and men aged 18 to 70 years with an ICD-10 diagnosis of a depressive episode of depressive disorder (F32), recurrent depressive disorder (F33), or bipolar disorder (F31) * moderate or severe current episode prior to initial open iTBS treatment (HAMD-21 \>16 points) * response to iTBS treatment (either reduction in HAMD score by 50% or score at the end of treatment \<11 points) * no concomitant psychotic symptoms. * no other relevant psychiatric disorder as assessed by the study physician * residence in Germany and German speaking that allows understanding of the information provided * patient is capable of giving consent Exclusion Criteria: * fulfillment of the general contraindications for TMS (electrical implants or metallic objects in the body such as pacemakers or insulin pumps). * severe neurological diseases (e.g., cerebrovascular events, neurodegenerative diseases, epilepsy, malformations of the brain, severe head injury in the history) * current harmful use or dependence on alcohol, amphetamines, cocaine, benzodiazepines, anticonvulsants, or opiates * acute suicidality * pregnancy * current participation in another study
Conditions Her-2 Negative Breast Cancer, HRR Gene M...
Phase PHASE2
Enrollment 66
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This study is to evaluate the efficacy and safety of combination of Camrelizumab (Immunotherapy, PD-1 inhibitor), Fluzoparib (PARP inhibitor) and Nab-paclitaxel in neoadjuvant therapy of Her-2 negative breast cancer patients with HRR gene mutation.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Camrelizumab — Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle. Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.
  • Drug: Fluzoparib — Fluzoparib
  • Drug: Nab-paclitaxel — Nab-paclitaxel

Primary Outcomes

  • Pathologic Complete Response (pCR) (Up to 32 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-05-06
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 66 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ying Lin
Principal Investigators:
  • Ying Lin, MD (STUDY_CHAIR) - Principal Investigator
Contact Information
Study Contact:
Ying Lin, MD
+8602087755766
linying3@mail.sysu.edu.cn
Xiaying Kuang, MD
+8602087755766
kuangxy5@mail.sysu.edu.cn
Ying Lin, MD
+8602087755766
linying3@mail.sysu.edu.cn
First Affiliated Hospital, Sun Yat-Sen University
Interventions
  • Drug: Camrelizumab — Camrelizumab at a fixed dose of 200mg via IV infusion on Days 1 each 21-day cycle. Fluzoparibat at a fixed dose of 100mg BID, each 21-day cycle. Nab-paclitaxel at a fixed dose of 260 milligrams via intravenous (IV) infusion on Days 1 each 21-day cycle.
  • Drug: Fluzoparib — Fluzoparib
  • Drug: Nab-paclitaxel — Nab-paclitaxel
Study Locations (1 sites)
First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong 510080 China
Eligibility Criteria
Inclusion Criteria: * Histologically documented Her-2 negative * TNM stage: T1c, N1-N2;T2-4, N0-N2;any T, N3 * No distant metastatic disease * Eastern Cooperative Oncology Group Performance Status: 0\~1 * HRR gene mutation: at least one pathogenic or likely pathogenic variant in germline or somatic BRCA1, BCRA2 and PALB2 genes, or in germline ATM, BARD1, BRIP1, CDK12, CHEK2, RAD51C, RAD51D genes. Exclusion Criteria: * Patients who are pregnant or lactating at the time of randomization or refuse to contraception. * Patients who have other malignant diseases within 2 years, except for cured skin basal cell carcinoma, breast carcinoma in situ or cervical carcinoma in situ * Patients with psychiatric disorder, peripheral or central nerve system disease or any disorder, which compromises ability to give informed consent or participate in this study. * Patients who have myocardial infarction or congestive heart failure, or other serious cardiac disease. * Patients who have used immunosuppressive drug or corticosteroids within 14 days. * Patients who have other diseases which researchers. * Patients who allergy to any of the drugs in this trail.
Conditions Stage II Breast Cancer, Stage I Breast C...
Phase Not Applicable
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

There are controversies about breast implant-based reconstruction techniques. Our center pioneered single-port insufflation endoscopic nipple-sparing mastectomy (SIE-NSM) combined with stage I prosthesis reconstruction. The study's primary objective is to compare single-port endoscopic NSM combined with pre-pectoral breast reconstruction to the subpectoral breast reconstruction group regarding breast satisfaction. This study is an ambispective cohort study. The study will be conducted at Beijing Friendship Hospital, affiliated with Capital Medical University. Patients will be enrolled retrospectively from January 2014 to March 2022 by reviewing the medical records and recruited prospectively from March 2022 to March 2025. The two cohorts are the pre-pectoral breast reconstruction cohort and the subpectoral breast reconstruction cohort, both following single-port insufflation endoscopic nipple-sparing mastectomy. The primary outcome of this study is postoperative breast satisfaction, which the BREAST-Q score will measure. The different variables will be compared using the Χ2 test for categorical variables and the Mann-Whitney test for continuous variables.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Procedure: The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy — Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction

Primary Outcomes

  • breast satisfaction (12 months after operation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-03-01
Completion: 2027-03
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Beijing Friendship Hospital
Collaborators: Beijing Health Promotion Association
Principal Investigators:
  • guoxuan gao, MD (PRINCIPAL_INVESTIGATOR) - Department of General Surgery, Beijing Friendship Hospital, Capital Medical University
Contact Information
Study Contact:
guoxuan gao, MD
+861063138712
aliceggx@163.com
guoxuan Guo
+861063138712
aliceggx@163.com
Beijing Friendship Hospital, Capital medical University
Interventions
  • Procedure: The breast reconstruction method after single-port insufflation endoscopic nipple-sparing mastectomy — Group A:The prepectoral breast reconstruction. Group B:The subpectoral breast reconstruction
Study Locations (1 sites)
Beijing Friendship Hospital, Capital medical University, Beijing, Beijing Municipality China
Eligibility Criteria
Inclusion Criteria: 1. Female patients with preoperative pathologically confirmed early-stage invasive breast cancer (stage I or stage II) by core needle biopsy. 2. Breast-conserving surgery is not possible due to the presence of contraindications to breast-conserving surgery, or the patient actively requests total mastectomy. 3. Patients having willingness for breast reconstruction. 4. Age between 18 to 70 years. 5. Maximum diameter of the cancer lesion ≤ 3 cm. 6. Physical examination and breast magnetic resonance imaging (MRI) confirmed that the tumor did not invade the skin, subcutaneous tissue, or chest wall. 7. The distance between the lesion and the nipple is ≥2 cm, and it is confirmed by physical examination and MRI that the nipple-areola complex is not invaded. 8. Eastern Cooperative Oncology Group (ECOG) Performance Status Scale of 0 to 2. Exclusion Criteria: 1. patients having serious medical diseases, including unstable angina pectoris, myocardial infarction, and cerebrovascular accident within 6 months. 2. Having history of malignant tumor (s) within 5 years. 3. Patients under immunosuppressive therapy for organ transplantation. 4. Having continuous systemic steroid hormone therapy. 5. Pregnant or lactating women.
Conditions Advanced Breast Cancer
Phase NA
Enrollment 36
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) as salvage treatment in patients with HER2-low advanced breast cancer who have received up to one previous chemotherapy for recurrent or metastatic disease without previous use of antibody-drug conjugate.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Disitamab vedotin — 2.0mg/kg, iv, day1, every 2 weeks

Primary Outcomes

  • Objective Response Rate (ORR) (From the date of starting Disitamab Vedotin to the date of first documentation of progression or death (up to approximately 1 year))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-04
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 36 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: RenJi Hospital
Principal Investigators:
  • Wenjin Yin, M.D. (PRINCIPAL_INVESTIGATOR) - Renji Hospital,School of Medicine, Shanghai Jiaotong University
Contact Information
Study Contact:
Wenjin Yin, M.D.
86(21)68385569
yinwenjin@renji.com
Wenjin Yin
86(21)68385569
yinwenjin@renji.com
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Interventions
  • Drug: Disitamab vedotin — 2.0mg/kg, iv, day1, every 2 weeks
Study Locations (1 sites)
Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, 200127 China
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥18 years * Expected survival ≥12 weeks * ECOG 0-1 * Histologically confirmed invasive advanced or metastatic breast cancer that is incurable and unresectable * At least one measurable lesion according to the RECIST 1.1 * No history of antibody-drug conjugate use * Up to one previous chemotherapy for advanced disease * Available hormone receptor status. Hormone receptor-positive subjects are allowed to receive no more than two previous endocrine therapy for advanced disease * HER2-low tumors, defined as IHC1+ or IHC2+ with negative FISH test; or HER2-ultralow tumors, defined as incomplete and faint membrane staining in \>0 but ≤10% of tumor cells * Adequate organ function Exclusion Criteria: * History of thromboembolic events * Uncontrolled systemic diseases, including diabetes, hypertension, interstitial lung disease, cirrhosis, etc. * Active infections requiring systemic treatment * Pregnant or lactating * Presence of brain metastases and/or carcinomatous meningitis
Conditions Mood Disorder of Depressed Type
Phase NA
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Logotherapy can help people find their meaning in life and help people reduce their suicidal ideation. Suicide was the second leading cause of death for 15-24 year-olds. Logotherapy can increase exploration of meaning in life for adolescents and prevent them from attempting suicide. However, most research only explored the effects of logotherapy on meaning in life and depression in adolescents with mood disorders. There is a lack of research to explore the effects of logotherapy on anxiety and suicidal ideation in adolescents. Therefore, this study will explore the effects of logotherapy on meaning in life, depression, anxiety and suicidal ideation in adolescents with mood disorders. This study will carry on for two years and the sample will be recruited from the adolescents' outpatient clinic of psychiatric department in hospitals. The first and second year of the study will use a single-blind randomized controlled trial approach, the aim is to evaluate the short-term and longitudinal effects of logotherapy meaning in life, depression, anxiety and suicidal ideation in adolescents with mood disorders, the sample will collect 120 adolescents with mood disorders, and will use four instruments for testing the logotherapy intervention. The four instruments are: (1) Purpose in life Test, (2) Beck Depression Inventory II, (3) Beck Anxiety Inventory, (4) Beck Scale for Suicide Ideation. Data will be analyzed using the Statistic Package for the Social Science. The result of this study will be applied to the mental health team in the clinical psychiatric department for taking care of patients, and help adolescents with mood disorders to find their meaning in life, further, to reduce their depression, anxiety and suicidal ideation.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Other: logotherapy — The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.

Primary Outcomes

  • Purpose in life Test-1 (pre-test (before intervention))
  • Purpose in life Test-2 (post-test 1 (the week after the intervention))
  • Purpose in life Test-3 (post-test 2 (three months after the intervention))
  • Purpose in life Test-4 (post-test 3 (nine months after the intervention))
  • Beck Depression Inventory II-1 (pre-test (before intervention))
  • Beck Depression Inventory II-2 (post-test 1 (the week after the intervention))
  • Beck Depression Inventory II-3 (post-test 2 (three months after the intervention))
  • Beck Depression Inventory II-4 (post-test 3 (nine months after the intervention))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-05-19
Completion: 2025-07-31
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National Taiwan University Hospital
Collaborators: Kaoshiung Chang Gung Memorial Hospital
Principal Investigators:
  • Fan-Ko Sun, PhD (STUDY_CHAIR) - Second Degree Bachelor of Science in nursing, National Taiwan University
Contact Information
Study Contact:
Fan-Ko Sun, PhD
+886-2-33669702
sunfanko@ntu.edu.tw
Chun-Ying Chiang, PhD
+886-7-6151100
chunying@isu.edu.tw
Fan-Ko Sun, PhD
0952624135
sunfanko@ntu.edu.tw
Kaohsiung Chang Gung Memorial Hospital
Interventions
  • Other: logotherapy — The logotherapy is carried out in an individual way in this study. The full-time assistant will give the experimental group 3 months of logotherapy intervention by interviewing with the participant, once every two weeks, about 1-2 hours each time, a total of 6 times of logotherapy to guide the participant to find the meaning of his life and value.The location is mainly in the hospital when the participant has to return for consultation, or at the participant's home.
Study Locations (1 sites)
Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Niaosong District 833 Taiwan
Eligibility Criteria
Inclusion Criteria: * Patients with mood disorders (such as depression, bipolar disorder) diagnosed by a psychiatrist. * Patient Health Questionnaire-9 items (PHQ-9) score 5-19 points (indicating mild depression to moderate to severe depression) * Agree to participate in logotherapy * Able to participate in logotherapy Exclusion Criteria: * Patients with severe emotional disorders who cannot participate in logotherapy. * Those who have severe psychopathological phenomena and cannot judge reality or those who are mentally deficient. * Those who have serious suicidal ideation or clear suicide plan are not suitable for interview
Conditions Breast Cancer Female, Breast Cancer Recu...
Phase NA
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Purpose To investigate the ability of 18F-FDG PET/CT imaging to detect metastases not detected by conventional imaging (CT and bone scintigraphy) in patients diagnosed with stage II/III and locoregional recurrent breast cancer (BC) which can affect the choice of treatment. Hypothesis The hypothesis is that 18F-FDG PET/CT can provide information about disease stage beyond the currently used conventional imaging (CT and bone scintigraphy) in patients diagnosed with stage II/III or locoregional recurrent BC. Objectives Primary: To evaluate if a 18F-FDG PET/CT scan in the initial work up of patients diagnosed with stage II/III or locoregional recurrent BC will lead to change in staging and/or treatment. Secondary: * Overall survival (OS) and progression-free survival (PFS) in the patients with upstaging based on findings on 18F-FDG PET/CT scan compared with the patients with unchanged stage of disease following 18F-FDG PET/CT. * Obtain size of the primary BC from CT/MRI scan and evaluate if these metrics are correlated to outcome. * Obtain PET parameters from the primary BC: maximum, mean, and peak standardized uptake value (SUVmax, SUVmean, SUVpeak), metabolic tumour volume (MTV), total lesion glycolysis (TLG), total MTV and total TLG and evaluate if these metrics are correlated with outcome. * Obtain CT and PET texture parameters from the primary BC and evaluate if these metrics are correlated with outcome. * Blood and tumor samples for molecular characterisation:

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Single

Interventions / Regimen

  • Other: 18F-FDG PET/CT — Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.

Primary Outcomes

  • Change in staging and/or management due to added 18F-FDG PET/CT scan (5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-02-16
Completion: 2032-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vestre Viken Hospital Trust
Principal Investigators:
  • Harald Grut, MD, PHD (PRINCIPAL_INVESTIGATOR) - Vestre Viken Hospital Trust
Contact Information
Study Contact:
Harald Grut, MD, PHD
004797108503
harald.grut@gmail.com
Harald Grut, MD, PHD
Drammen Hospital - Vestre Viken HF
Interventions
  • Other: 18F-FDG PET/CT — Included breast cancer patients will undergo a 18F-FDG PET/CT scan in addition to conventional imaging with CT and bone scintigraphy.
Study Locations (1 sites)
Drammen Hospital - Vestre Viken HF, Drammen, N-3004 Norway
Eligibility Criteria
Inclusion Criteria: * Patients with high risk primary or recurrent breast cancer * Non pregnant women \> 18 years * Not receiving active treatment of other cancer types. * Eastern Cooperative Oncology Group (ECOG) status 0-2. Exclusion Criteria: * Pregnant woman * Males * Age under 18 * Patients receiving active treatment for other cancers * Poor general conditipon (ECOG 3 or higher)
Conditions Major Depressive Disorder
Phase NA
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this study is to evaluate whether rtfMRI-nf training to increase the amygdala response to positive memories may serve as a stand-alone intervention for major depressive disorder

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: Amygdala real-time fMRI neurofeedback — Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
  • Device: Sham feedback — Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories

Primary Outcomes

  • Beck Depression Inventory (BDI-II) (baseline vs up to one year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-06-01
Completion: 2028-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Kymberly Young
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Kymberly Young, PhD (PRINCIPAL_INVESTIGATOR) - University of Pittsburgh
Contact Information
Study Contact:
Kymberly Young, PhD
412-648-6179
youngk@pitt.edu
Lisa Stupar
412-383-8100
stuparlm@upmc.edu
Kymberly Young, PhD
youngk@pitt.edu
University of Pittsburgh
Interventions
  • Device: Amygdala real-time fMRI neurofeedback — Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
  • Device: Sham feedback — Participants are shown activity from another participant's left amygdala who previously completed the task and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
Study Locations (1 sites)
University of Pittsburgh, Pittsburgh, Pennsylvania 15261 United States
Eligibility Criteria
Inclusion Criteria: * ages 18 - 55 * primary diagnosis of MDD and are currently depressed * able to give written informed consent prior to participation * unmedicated OR are stable on an antidepressant regime (at least 4 weeks to ensure symptoms are stable). Effective medications will not be discontinued for the purposes of the study. Exclusion Criteria: * clinically significant or unstable cardiovascular, pulmonary, endocrine, neurological, gastrointestinal illness or unstable medical disorder * Current severe DSM-V alcohol or substance use disorder, with the exception of nicotine or caffeine. Clinician will access subjects' alcohol and substance use on a case-by-case to determine whether specific cases of mild or moderate alcohol or substance use would also interfere with the effects of the intervention. * history of traumatic brain injury * unable to complete MRI scan due to claustrophobia or general MRI exclusions (e.g., shrapnel inside body) * currently pregnant or breast feeding * unable to complete questionnaires written in English * current (within 3 weeks of testing) use of any antipsychotics, anticonvulsants, stimulants, benzodiazepines, beta-blockers, or other medications (except antidepressants) likely to influence cerebral blood flow. Effective medications will not be discontinued for the purposes of the study. * diagnosis of psychotic or organic mental disorder, bipolar I or II disorder. * eye problems or difficulties in corrected vision.
Conditions Diabetes Mellitus, Type 2, Stroke (CVA) ...
Phase PHASE4
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A human subjects research study, the primary purpose of which is to assess the EFFECTS OF SEMAGLUTIDE ON INTRACRANIAL BLOOD FLOW AND BLOOD-BRAIN BARRIER PERMEABILITY IN TYPE-2 DIABETES (T2D) through testing of the intervention on patients in a clinical setting. The study will randomize subjects with diabetes to either semaglutide or matching placebo. Magnetic resonance images will be primary endpoint measured at baseline and at one year to assess effect of this FDA approved medication. Given the available evidence supporting the neuroprotective effect of this drug class and stroke reduction with semaglutide, and the investigators preliminary data showing that T2D had significantly reduced total number of distal arterial branches in the brain than non-T2D, the investigators expect treatment with semaglutide will be associated with improved intracranial blood flow condition.

Design

Study type: Interventional Phases: Phase4 Allocation: Randomized Intervention model: Parallel Primary purpose: Screening Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: Semaglutide Auto-Injector — Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist. At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively. The target dose for subjects is 1mg per week up to the 52 week treatment duration.
  • Other: Placebo — Placebo

Primary Outcomes

  • Intracranial blood flow (IBF) (Approximately 12 Months)
  • bloodbrain barrier Ktrans (Approximately 12 Months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2024-01-11
Completion: 2026-12-31
Eligibility
Age: 40 Years and older
Sex: ALL
Volunteers: false
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: Novo Nordisk A/S
Principal Investigators:
  • Francis Kim, MD (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Francis Kim, MD
206-744-8305
fkim@u.washington.edu
Francis Kim, MD
206-744-8305
fkim@u.washington.edu
University of Washington - Harborview Medical Center
Francis Kim, MD
University of Washington - Harborview Medical Center
Interventions
  • Drug: Semaglutide Auto-Injector — Subjects have an equal chance of receiving semaglutide or placebo. Which treatment subjects receive is decided at random by a computer (purely by chance, like the tossing of a coin). Neither subjects, Study Site personnel nor image reviewers will know which treatment subjects are assigned to. The study drug must be taken weekly. The subject's other medications may be changed by the study's un-blinded Endocrinologist. At baseline subject will receive and take home 0.25mg injector for use 3 more times. They will be given a 0.5mg injector and a 1mg injector for use beginning 5 and 9 weeks from baseline respectively. The target dose for subjects is 1mg per week up to the 52 week treatment duration.
  • Other: Placebo — Placebo
Study Locations (1 sites)
University of Washington - Harborview Medical Center, Seattle, Washington 98104 United States
Eligibility Criteria
Inclusion Criteria: 1. Men and women 40-65 years of age 2. Subjects with type-2 diabetes \>= 3 years and HbA1C 7%-10% with blood sugar control medications including insulin, metformin, sulfonylureas, or SGLT2 inhibitors 3. Medically stable 4. Has not received any investigational drug in the past 6 months 5. Willing to participate and sign informed consent. Exclusion Criteria: 1. Contraindication to MRI or contrast agent 2. eGFR\<45 mL/min/1.73m2 (eGFR is a measurement of kidney function) 3. Currently treated with glucagon-like peptide-1 receptor antagonist (same drug class as study intervention) 4. Unable to perform home-glucose monitoring 5. Currently need more than 100 units of insulin daily 6. Uncontrolled hypertension with systolic blood pressure (SBP)\>180 mmHg or diastolic blood pressure (DBP)\>100 mmHg 7. LDL-C\>130 mg/dL or not on stable statin therapy in the past 6 months 8. Treatment with pioglitazone in the past 3 months 9. History of pancreatitis 10. History of myocardial infarction, stroke or transient ischemic attack 11. History or family history of Medullary Thyroid Carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) 12. Hypersensitivity to semaglutide or any of the product components 13. Participating in other clinical trial 14. Women of child-bearing potential (ie, those who are not chemically or surgically sterilized or who are not post-menopausal) who have a positive pregnancy test at enrollment or who are breastfeeding or who plan to become pregnant in the next 15 months.
Conditions Triple-negative Breast Cancer
Phase PHASE2
Enrollment 120
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II, open-label, Single-center platform study research based on molecular subtypes to explore precision therapy in refractory triple-negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: A1: SHR-A1811 — A1: an anti-HER2 antibody-drug conjugate (ADC)
  • Drug: A2: SHR-A1811 with Camrelizumab with famitinib — A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) Camrelizumab: an anti-programmed death-1 (PD-1) antibody
  • Drug: B1: TROP2 ADC — B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
  • Drug: B2: TROP2 ADC with Camrelizumab — B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC Camrelizumab: an anti-programmed death-1 (PD-1) antibody
  • Drug: C1: SHR-A1811 — C1: an anti-HER2 antibody-drug conjugate (ADC)
  • Drug: C2: SHR-A1811 with BP102 — C2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)
  • Drug: D1: TROP2 ADC — D1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
  • Drug: D2: TROP2 ADC with BP102 — D2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC BP102: a humanized recombinant monoclonal IgG1 antibody (biosimilar to bevacizumab)

Primary Outcomes

  • Overall response rate (ORR) (Randomization until the first occurrence of disease progression or death from any cause, which ever occurs first, through the completion of study (approximately 3 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-03-30
Completion: 2028-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 120 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Principal Investigators:
  • Zhimin Shao, M.D. (PRINCIPAL_INVESTIGATOR) - Fudan University
Contact Information
Study Contact:
Zhimin Shao, M.D.
+86-021-64175590
zhimingshao@yahoo.com
Yin Liu, M.D.
+86-021-64175590
liuyinfudan@163.com
Zhimin Shao, M.D.
zhimingshao@yahoo.com
Fudan University Shanghai Cancer Center
Interventions
  • Drug: A1: SHR-A1811 — A1: an anti-HER2 antibody-drug conjugate (ADC)
  • Drug: A2: SHR-A1811 with Camrelizumab with famitinib — A2: SHR-A1811: an anti-HER2 antibody-drug conjugate (ADC) Camrelizumab: an anti-programmed death-1 (PD-1) antibody
  • Drug: B1: TROP2 ADC — B1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
  • Drug: B2: TROP2 ADC with Camrelizumab — B2: TROP2 ADC : an Trophoblast cell-surface antigen 2 (TROP2) ADC Camrelizumab: an anti-programmed death-1 (PD-1) antibody
  • Drug: C1: SHR-A1811 — C1: an anti-HER2 antibody-drug conjugate (ADC)
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Female aged ≥18 years; 2. TNBC invasive breast cancer confirmed by histology (specific definition: ER \<1% positive tumor cells by immunohistochemistry are defined as ER negative, PR \<1% positive tumor cells are defined as PR negative, HER2 0-1+ or HER2 ++ but negative by FISH without amplification was defined as HER2 negative); Locally advanced breast cancer (unable to undergo radical local treatment) or recurrent metastatic breast cancer; 3. Progression after at least one prior therapeutic regimens for advanced/metastatic TNBC 4. At least one measurable lesion according to RECIST 1.1 (conventional CT scan ≥20 mm, spiral CT scan ≥10 mm, measurable lesion has not received radiotherapy); 5. The functions of the main organs are basically normal and meet the following conditions: i. Blood routine examination criteria shall meet: HB ≥90 g/L (no blood transfusion within 14 days); The ANC acuity 1.5 x 10\^9 /L; PLT acuity 75 x 10\^9 /L; ii. Biochemical tests should meet the following criteria: TBIL ≤1.5×ULN (upper limit of normal value); ALT and AST ≤3×ULN; If liver metastases were present, ALT and AST≤ 5×ULN; Serum Cr ≤1×ULN, endogenous creatinine clearance \> 50 ml/min (Cockcroft-Gault formula); 6. They have not received radiotherapy, molecular targeted therapy, or surgery within 3 weeks before the start of the study, and have recovered from the acute toxicity of previous treatment (if surgery was performed, the wound has healed completely); No peripheral neuropathy or grade I peripheral neurotoxicity; 7. ECOG score ≤1, and life expectancy ≥3 months; 8. Fertile female subjects were required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last use of the study drug; 9. Subjects volunteered to join the study, signed informed consent, had good compliance, and cooperated with follow-up. Exclusion Criteria: 1. Radiotherapy (except for palliative causes), chemotherapy, and immunotherapy were used in the first 3 weeks of treatment, except bisphosphonate (which can be used for bone metastasis); 2. Uncontrolled central nervous system metastases (indicating symptomatic or symptomatic treatment with glucocorticoids or mannitol); 3. A history of clinically important or uncontrolled heart disease, including congestive heart failure, angina pectoris, myocardial infarction, or ventricular arrhythmia within the last 6 months; 4. Persistent grade 1 or higher adverse reactions caused by previous treatments. The exception to this is hair loss or something the researchers don't think should be ruled out. Such cases should be clearly documented in the investigator's notes; 5. Underwent major surgery (except minor outpatient procedures, such as placement of vascular access) within 3 weeks of the first course of trial treatment; 6. Pregnant or lactating patients; 7. Malignancy (except basal cell carcinoma of the skin, which has been cured, and carcinoma in situ of the cervix) in the past 5 years.
Conditions Depression, Anxiety, Mental Health Issue
Phase Not Applicable
Enrollment 500
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Participation in endurance sports has been increasing over the last few decades and our aim of our exploratory descriptive survey study is therefore to examine mental health issues in endurance athletes (marathon runners, ultra endurance runners, triathletes), employing the IOC assessment tool, to provide information on mental health issues in this population. Secondary objects are to evaluate risk factors for mental health issues in endurance athletes (like exercise behaviour, competition behaviour, age, gender, medical issues)

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Behavioral: mental health issues — survey on mental health issues in endurance athletes

Primary Outcomes

  • Number of participants with mental health issues (March-September 2023)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-03-15
Completion: 2025-09-30
Eligibility
Age: 16 Years and older
Sex: ALL
Volunteers: true
Enrollment: 500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Ultra Sports Science Foundation
Collaborators: Hospital Universitario del Vinalopo, Universidade do Porto, University of South Africa
Principal Investigators:
  • Volker Scheer, Prof (PRINCIPAL_INVESTIGATOR) - Ultra Sports Science Foundation
Contact Information
Study Contact:
Volker Scheer, Prof
+33 4 25 36 79 54
contact@ultrasportsscience.org
Volker Scheer, Prof
+33 (0)4 25 36 79 54
contact@ultrasportsscience.org
Ultra Sports Science Foundation
Interventions
  • Behavioral: mental health issues — survey on mental health issues in endurance athletes
Study Locations (1 sites)
Ultra Sports Science Foundation, Pierre-Bénite, 69310 France
Eligibility Criteria
Inclusion Criteria: * endurance athletes (marathon runners, ultramarathon runners and triathletes) * over the age of 16 * all genders * recreational athletes (non- elite) * elite athletes (professional, international, college level) Exclusion Criteria: * athletes that that are not competing or have not competed in an official endurance race * athletes that are younger than 16 years of age.
Conditions Malignant Neoplasm, PET/CT, Non-Small Ce...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. Integrin αvβ6 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous or reconstructed epithelial cells. A new PET probe, 68Ga-Trivehexin, targeting integrin αvβ6 has been developed with better affinity and selectivity than previous probes. Clinical data supports its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of tumors, providing a new and precise evaluation method for malignant tumors.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Diagnostic Test: PET/CT scans — Diagnostic Test: For 68Ga-Trivehexin PET/CT, no special preparation was required. Approximately 50 min after an i.v. administration of \[68Ga\]Ga-Trivehexin with a dose of 1.85-2.22 MBq/kg, and the PET acquisition time was 2.5 min per bed.

Primary Outcomes

  • The diagnostic sensitivity and specificity of 68Ga-Integrin αvβ6 PET/CT in the staging of malignant tumors (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-01-01
Completion: 2025-12-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhongnan Hospital
Principal Investigators:
  • Yong He, MD, PhD (PRINCIPAL_INVESTIGATOR) - Zhongnan Hospital
Contact Information
Study Contact:
Yong He, MD, PhD
+86-27-67812698
vincentheyong@163.com
Lei Zheng
+86-27-67812787
Zhongnan Hospital of Wuhan University
Yong He, MD, PhD
Zhongnan Hospital of Wuhan University
Interventions
  • Diagnostic Test: PET/CT scans — Diagnostic Test: For 68Ga-Trivehexin PET/CT, no special preparation was required. Approximately 50 min after an i.v. administration of \[68Ga\]Ga-Trivehexin with a dose of 1.85-2.22 MBq/kg, and the PET acquisition time was 2.5 min per bed.
Study Locations (1 sites)
Zhongnan Hospital of Wuhan University, Wuhan, Hubei 430071 China
Eligibility Criteria
Inclusion Criteria: * Participants with newly diagnosed malignant tumor confirmed by pathology or suspected lung cancer; * Age ≥18 years, regardless of gender; * No prior anti-tumor therapy (e.g., chemotherapy, radiotherapy, targeted therapy, or immunotherapy) before PET/CT; * Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1; * Female subjects of reproductive age, male subjects and their partners agree to use reliable contraceptive measures (e.g., abstinence, birth control pills, injectable contraceptives, or subcutaneous contraceptive implants) until 6 months after the completion of the study; * Participants should voluntarily consent to the clinical trial, and have the ability to understand and sign an informed consent form. Exclusion Criteria: * Known allergy to injection or its excipients; * Severe liver or renal dysfunction; * Claustrophobia or other psychiatric disorders; * History of other malignant tumors; * Participation in another clinical trial within 30 days prior to PET/CT scan; * Pregnant or breastfeeding women; * Refusal to participate or request for withdrawing from the clinical study; * Other conditions deemed unsuitable for inclusion by investigator.